Furthermore, IHCCs and GBCs displayed a statistically significant prevalence of potential positive predictive biomarkers for immune checkpoint inhibition (programmed death-ligand 1 [PD-L1] expression, high microsatellite instability, and high tumor mutational burden) compared with EHCCs. This evidence concerns the gene CD274 and neoplasm.